Mereo BioPharma
MREO
63 hedge funds and large institutions have $58.5M invested in Mereo BioPharma in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 10 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
0.6% less ownership
Funds ownership: 11.48% → 10.88% (-0.6%)
2% less funds holding
Funds holding: 64 → 63 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
23% less call options, than puts
Call options by funds: $162K | Put options by funds: $211K
29% less capital invested
Capital invested by funds: $82.7M → $58.5M (-$24.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$9.79M |
| 2 |
CC
Clearline Capital
New York
|
+$1.1M |
| 3 |
Renaissance Technologies
New York
|
+$764K |
| 4 |
Millennium Management
New York
|
+$675K |
| 5 |
Alkeon Capital Management
New York
|
+$489K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$7.82M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$2.17M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$690K |
| 4 |
E
Ergoteles
New York
|
-$593K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$431K |
MREO Hedge Fund Activity: Q3 2022 in Review
63 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q3 2022, worth a combined $58.5M — down 29% from $82.7M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of MREO and 9 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 21 added.
The largest buyer was OrbiMed, adding an estimated $9.79M. The largest seller was Rubric Capital Management (New York), cutting an estimated $7.82M.
- 63 institutional investors held Mereo BioPharma (MREO) as of Q3 2022, down from 64 in Q2 2022.
- Funds reported $58.5M of Mereo BioPharma stock for Q3 2022, down 29% quarter-over-quarter.
- 9 funds opened new Mereo BioPharma positions in Q3 2022 and 10 closed out, a net change of -1 holder.
- The largest Mereo BioPharma buyer in Q3 2022 was OrbiMed, an estimated $9.79M added.
- The largest Mereo BioPharma seller in Q3 2022 was Rubric Capital Management (New York), an estimated $7.82M sold.
Based on aggregated 13F filings for Q3 2022.